JP2015508411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508411A5 JP2015508411A5 JP2014551726A JP2014551726A JP2015508411A5 JP 2015508411 A5 JP2015508411 A5 JP 2015508411A5 JP 2014551726 A JP2014551726 A JP 2014551726A JP 2014551726 A JP2014551726 A JP 2014551726A JP 2015508411 A5 JP2015508411 A5 JP 2015508411A5
- Authority
- JP
- Japan
- Prior art keywords
- layer
- optionally
- subcoating
- nucleus
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000010410 layer Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000009498 subcoating Methods 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000011247 coating layer Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 2
- 229960003089 pramipexole Drugs 0.000 claims description 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 2
- 229960000245 rasagiline Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261585824P | 2012-01-12 | 2012-01-12 | |
| US61/585,824 | 2012-01-12 | ||
| PCT/IL2013/050025 WO2013105092A1 (en) | 2012-01-12 | 2013-01-10 | Fixed dose combination therapy of parkinson's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508411A JP2015508411A (ja) | 2015-03-19 |
| JP2015508411A5 true JP2015508411A5 (https=) | 2017-05-18 |
| JP6243351B2 JP6243351B2 (ja) | 2017-12-06 |
Family
ID=48781101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551726A Active JP6243351B2 (ja) | 2012-01-12 | 2013-01-10 | パーキンソン病の固定投与量薬剤組合せ治療 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20150079187A1 (https=) |
| EP (1) | EP2802319B1 (https=) |
| JP (1) | JP6243351B2 (https=) |
| KR (2) | KR102276896B1 (https=) |
| CN (1) | CN104168896B (https=) |
| AU (1) | AU2013208653B2 (https=) |
| CA (1) | CA2860952C (https=) |
| CY (1) | CY1119793T1 (https=) |
| DK (1) | DK2802319T3 (https=) |
| ES (1) | ES2655676T3 (https=) |
| HU (1) | HUE038029T2 (https=) |
| IL (1) | IL233572B (https=) |
| IN (1) | IN2014MN01568A (https=) |
| LT (1) | LT2802319T (https=) |
| MX (1) | MX360409B (https=) |
| NO (2) | NO2802319T3 (https=) |
| PL (1) | PL2802319T3 (https=) |
| PT (1) | PT2802319T (https=) |
| RS (1) | RS56742B1 (https=) |
| RU (1) | RU2642962C9 (https=) |
| WO (1) | WO2013105092A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5769923B2 (ja) | 2006-04-03 | 2015-08-26 | テバ ファーマシューティカル インダストリーズ リミティド | レストレスレッグス症候群の治療のためのラサギリンの使用 |
| CN104367565A (zh) * | 2014-11-21 | 2015-02-25 | 哈尔滨圣吉药业股份有限公司 | 一种盐酸普拉克索缓释微丸 |
| CN105147627B (zh) * | 2015-08-19 | 2019-04-12 | 天津红日药业股份有限公司 | 一种含有盐酸普拉克索的药物组合物及其制备方法 |
| EP3668501A4 (en) * | 2017-08-17 | 2021-03-17 | Zi-Qiang Gu | MONOAMINE PAMOATE SALTS ANTI-PARKINSON AGENTS, THEIR PREPARATION AND USE |
| KR20210106477A (ko) * | 2018-12-19 | 2021-08-30 | 갈렉토 바이오테크 에이비 | 5-브로모피리딘-3-일 3-데옥시-3-[4-(3,4,5-트리플루오로페닐)-1h-1,2,3-트리아졸-1-일]-1-티오-알파-d-갈락토피라노사이드의 비정질 형태 |
| JP2023504876A (ja) * | 2019-12-06 | 2023-02-07 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 薬物組成物、キット及びその応用 |
| WO2023112024A1 (en) * | 2021-12-14 | 2023-06-22 | Pharma Two B Ltd. | Method of treating parkinson's disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL215263B1 (pl) * | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| WO2005070428A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist |
| AU2005215136A1 (en) * | 2004-02-20 | 2005-09-01 | Novartis Ag | DPP-IV inhibitors for treating neurodegeneration and cognitive disorders |
| WO2006014973A2 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| JP5769923B2 (ja) | 2006-04-03 | 2015-08-26 | テバ ファーマシューティカル インダストリーズ リミティド | レストレスレッグス症候群の治療のためのラサギリンの使用 |
| JP2010525018A (ja) * | 2007-04-24 | 2010-07-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物 |
| CN102105169B (zh) * | 2008-06-06 | 2014-09-10 | 图必制药公司 | 用于治疗帕金森病的药物组合物 |
| KR20110071064A (ko) * | 2008-08-19 | 2011-06-28 | 크놉 뉴로사이언시스 인코포레이티드 | (ｒ)-프라미펙솔을 사용하는 조성물 및 방법 |
| JP6045347B2 (ja) * | 2010-02-03 | 2016-12-14 | ファーマ ツー ビー リミテッド | ラサギリンの持続放出性製剤およびその使用 |
-
2013
- 2013-01-10 LT LTEP13736198.6T patent/LT2802319T/lt unknown
- 2013-01-10 EP EP13736198.6A patent/EP2802319B1/en active Active
- 2013-01-10 CN CN201380014052.8A patent/CN104168896B/zh active Active
- 2013-01-10 DK DK13736198.6T patent/DK2802319T3/da active
- 2013-01-10 WO PCT/IL2013/050025 patent/WO2013105092A1/en not_active Ceased
- 2013-01-10 HU HUE13736198A patent/HUE038029T2/hu unknown
- 2013-01-10 PT PT137361986T patent/PT2802319T/pt unknown
- 2013-01-10 PL PL13736198T patent/PL2802319T3/pl unknown
- 2013-01-10 NO NO13736198A patent/NO2802319T3/no unknown
- 2013-01-10 MX MX2014008537A patent/MX360409B/es active IP Right Grant
- 2013-01-10 KR KR1020147022416A patent/KR102276896B1/ko active Active
- 2013-01-10 IN IN1568MUN2014 patent/IN2014MN01568A/en unknown
- 2013-01-10 RS RS20180050A patent/RS56742B1/sr unknown
- 2013-01-10 RU RU2014132940A patent/RU2642962C9/ru active
- 2013-01-10 KR KR1020207002459A patent/KR20200013791A/ko not_active Ceased
- 2013-01-10 ES ES13736198.6T patent/ES2655676T3/es active Active
- 2013-01-10 CA CA2860952A patent/CA2860952C/en active Active
- 2013-01-10 AU AU2013208653A patent/AU2013208653B2/en active Active
- 2013-01-10 US US14/372,067 patent/US20150079187A1/en not_active Abandoned
- 2013-01-10 JP JP2014551726A patent/JP6243351B2/ja active Active
- 2013-09-30 NO NO13840443A patent/NO2901008T3/no unknown
-
2014
- 2014-07-09 IL IL233572A patent/IL233572B/en active IP Right Grant
-
2018
- 2018-01-17 CY CY20181100061T patent/CY1119793T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508411A5 (https=) | ||
| EA201071054A1 (ru) | Твердый препарат, растворяющийся во рту | |
| HRP20250181T1 (hr) | Spojevi i postupci za ciljanu razgradnju receptora androgena | |
| EA201591821A1 (ru) | Защищенные от несанкционированного использования фармацевтические составы | |
| WO2012131463A3 (en) | Controlled release pharmaceutical dosage forms | |
| WO2013009142A3 (en) | Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same | |
| MX2016014320A (es) | Composiciones de suspension de liberacion prolongada. | |
| CL2013002504A1 (es) | Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion | |
| JP2015147774A5 (https=) | ||
| JP2015523407A5 (https=) | ||
| WO2014059269A3 (en) | Multilayer compositions, coated devices and use thereof | |
| MX2015000114A (es) | Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada. | |
| WO2009059701A3 (de) | Retardtabletten mit hydromorphon | |
| JP2014218522A5 (https=) | ||
| HK1203815A1 (en) | Pharmaceutical compositions and methods for their preparation | |
| WO2011140446A3 (en) | Pharmaceutical formulations | |
| MX375936B (es) | Composiciones farmaceuticas mejoradas de pimobendan. | |
| BR112015030140A2 (pt) | forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral | |
| CR20150077A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
| WO2016142708A3 (en) | Pharmaceutical composition | |
| AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
| WO2011119288A3 (en) | Multilayer melt-extruded film | |
| WO2014181195A3 (en) | Antiemetic extended release solid dosage forms | |
| WO2013017910A8 (en) | Extended release pharmaceutical compositions containing paliperidone | |
| SI2612681T1 (sl) | Obložno sredstvo za farmacevtsko trdno obliko, farmacevtska filmska formulacija in obložena farmacevtska trdna oblika |